274 related articles for article (PubMed ID: 28118087)
1. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
[TBL] [Abstract][Full Text] [Related]
2. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
[TBL] [Abstract][Full Text] [Related]
3. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
[TBL] [Abstract][Full Text] [Related]
4. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.
Hammond SM; Hazell G; Shabanpoor F; Saleh AF; Bowerman M; Sleigh JN; Meijboom KE; Zhou H; Muntoni F; Talbot K; Gait MJ; Wood MJ
Proc Natl Acad Sci U S A; 2016 Sep; 113(39):10962-7. PubMed ID: 27621445
[TBL] [Abstract][Full Text] [Related]
5. Amphiphilic lipopeptide significantly enhances uptake of charge-neutral splice switching morpholino oligonucleotide in spinal muscular atrophy patient-derived fibroblasts.
Tajik-Ahmadabad B; Polyzos A; Separovic F; Shabanpoor F
Int J Pharm; 2017 Oct; 532(1):21-28. PubMed ID: 28864392
[TBL] [Abstract][Full Text] [Related]
6. Morpholino-Mediated Exon Inclusion for SMA.
Zhou H; Muntoni F
Methods Mol Biol; 2018; 1828():467-477. PubMed ID: 30171560
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
[TBL] [Abstract][Full Text] [Related]
8. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
[TBL] [Abstract][Full Text] [Related]
9. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
10. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
Nakevska Z; Yokota T
Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
13. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
14. Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.
Shabanpoor F; McClorey G; Saleh AF; Järver P; Wood MJ; Gait MJ
Nucleic Acids Res; 2015 Jan; 43(1):29-39. PubMed ID: 25468897
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.
Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S
Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820
[TBL] [Abstract][Full Text] [Related]
16. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
Porensky PN; Mitrpant C; McGovern VL; Bevan AK; Foust KD; Kaspar BK; Wilton SD; Burghes AH
Hum Mol Genet; 2012 Apr; 21(7):1625-38. PubMed ID: 22186025
[TBL] [Abstract][Full Text] [Related]
17. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
[TBL] [Abstract][Full Text] [Related]
18. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.
Zhou H; Janghra N; Mitrpant C; Dickinson RL; Anthony K; Price L; Eperon IC; Wilton SD; Morgan J; Muntoni F
Hum Gene Ther; 2013 Mar; 24(3):331-42. PubMed ID: 23339722
[TBL] [Abstract][Full Text] [Related]
19. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
[TBL] [Abstract][Full Text] [Related]
20. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration.
Aslesh T; Erkut E; Ren J; Lim KRQ; Woo S; Hatlevig S; Moulton HM; Gosgnach S; Greer J; Maruyama R; Yokota T
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36719755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
